Data Collection and Reporting
The authors discuss the need for a formal evaluation of the health equity impact of a new intervention, as these evaluations are hardly ever performed as part of a health technology assessment to understand its value. An evidence-based quantitative assessment of the health equity impact can help decision makers develop coverage policies, program designs, and quality initiatives focused on optimizing both total health and health equity, given the treatment options available. The authors outline the conceptual basis of how a new intervention can impact health equity and adopt distributional cost-effectiveness analysis based on decision-analytic models to assess this quantitatively, using a newly FDA-approved drug for Alzheimer’s disease (aducanumab) as an example.